FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Teva Pharmaceuticals Lidocaine Patch 5% Recall

Lidocaine Patch 5%, packaged in 30-count cartons, Rx only, Manufactured by: Actavis Lab…

Teva Pharmaceuticals USA · Parsippany, NJ

Risk level
Class II
Reported by FDA
Aug 19, 2020
Recall ID
D-1492-2020
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Lidocaine Patch 5% starting Jul 14, 2020. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1492-2020 on Aug 19, 2020. Reason: Labeling: Incorrect or Missing Lot and/or Exp date on the individual transdermal pouches but not in the carton. Status: Terminated.

Why it was recalled

Labeling: Incorrect or Missing Lot and/or Exp date on the individual transdermal pouches but not in the carton.

Product description

Lidocaine Patch 5%, packaged in 30-count cartons, Rx only, Manufactured by: Actavis Laboratories UT, Inc., Salt Lake City, UT 84108, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 0591-3525-30

Lot numbers, UPCs & expiration codes

Carton Lot # 1383513B, Patch Lot # 1383513, Exp date 03/2022

Where it was sold

Nationwide United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1492-2020
Classification
Class II
Status
Terminated
Recall initiated
Jul 14, 2020
FDA report date
Aug 19, 2020
Quantity
28,596 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA

Original FDA data

Every field from FDA enforcement report D-1492-2020, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
86017
Address
400 Interpace Pkwy
Code information
Carton Lot # 1383513B, Patch Lot # 1383513, Exp date 03/2022
Postal code
07054-1120
Report date
Aug 19, 2020
Product type
Drugs
Recall number
D-1492-2020
Classification
Class II
Recalling firm
Teva Pharmaceuticals USA
Product quantity
28,596 cartons
Termination date
Jul 7, 2021
Reason for recall
Labeling: Incorrect or Missing Lot and/or Exp date on the individual transdermal pouches but not in the carton.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Lidocaine Patch 5%, packaged in 30-count cartons, Rx only, Manufactured by: Actavis Laboratories UT, Inc., Salt Lake City, UT 84108, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 0591-3525-30
Distribution pattern
Nationwide United States
Recall initiation date
Jul 14, 2020
Initial firm notification
Letter
Center classification date
Aug 10, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1492-2020, published Aug 19, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls